Investigation of the antimycobacterial activity of African medicinal plants combined with chemometric analysis to identify potential leads

dc.contributor.authorMoyo, Phanankosi
dc.contributor.authorOfori, Michael
dc.contributor.authorBodede, Olusola S.
dc.contributor.authorWooding, Madelien
dc.contributor.authorKhorommbi, Ndivhuwo Kevin
dc.contributor.authorMcGaw, Lyndy Joy
dc.contributor.authorDanquah, Cynthia A.
dc.contributor.authorMaharaj, Vinesh J.
dc.contributor.emailvinesh.maharaj@up.ac.za
dc.date.accessioned2025-07-03T13:01:51Z
dc.date.available2025-07-03T13:01:51Z
dc.date.issued2024-06-25
dc.descriptionDATA AVAILABILITY : The datasets generated in this study are available from the corresponding author on reasonable request.
dc.description.abstractThe emergence of drug-resistant Mycobacterium tuberculosis strains is a threat to global health necessitating the discovery of novel chemotherapeutic agents. Natural products drug discovery, which previously led to the discovery of rifamycins, is a valuable approach in this endeavor. Against this backdrop, we set out to investigate the in vitro antimycobacterial properties of medicinal plants from Ghana and South Africa, evaluating 36 extracts and their 252 corresponding solid phase extraction (SPE) generated fractions primarily against the non-pathogenic Mycobacterium smegmatis and Mycobacterium aurum species. The most potent fraction was further evaluated in vitro against infectious M. tuberculosis strain. Crinum asiaticum (bulb) (Amaryllidaceae) emerged as the most potent plant species with specific fractions showing exceptional, near equipotent activity against the non-pathogenic Mycobacterium species (0.39 µg/ml ≤ MIC ≤ 25 µg/ml) with one fraction being moderately active (MIC = 32.6 µg/ml) against M. tuberculosis. Metabolomic analysis led to the identification of eight compounds predicted to be active against M. smegmatis and M. aurum. In conclusion, from our comprehensive study, we generated data which provided an insight into the antimycobacterial properties of Ghanaian and South African plants. Future work will be focused on the isolation and evaluation of the compounds predicted to be active.
dc.description.departmentParaclinical Sciences
dc.description.departmentChemistry
dc.description.librarianam2025
dc.description.sdgSDG-03: Good health and well-being
dc.description.urihttps://www.nature.com/srep/
dc.identifier.citationMoyo, P., Ofori, M., Bodebe, O.S. et al. 2024, 'Investigation of the antimycobacterial activity of African medicinal plants combined with chemometric analysis to identify potential leads', Scientific Reports, vol. 14, no. 14660, pp. 1-16. https://doi.org/10.1038/s41598-024-65369-7.
dc.identifier.issn2045-2322 (online)
dc.identifier.other10.1038/s41598-024-65369-7
dc.identifier.urihttp://hdl.handle.net/2263/103173
dc.language.isoen
dc.publisherNature Research
dc.rights© The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License.
dc.subjectMycobacterium tuberculosis (MTB)
dc.subjectTuberculosis (TB)
dc.subjectNatural products
dc.subjectPlants
dc.subjectMetabolomics
dc.subjectAntimicrobial drug resistance
dc.titleInvestigation of the antimycobacterial activity of African medicinal plants combined with chemometric analysis to identify potential leads
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Moyo_Investigation_2024.pdf
Size:
1.85 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: